Specific Recognition and Killing of Glioblastoma Multiforme by Interleukin 13-Zetakine Redirected Cytolytic T Cells
Kanwarpal Kahlon(City Of Hope National Medical Center), Michael C. Jensen(Seattle Children's Hospital), Laurence J.N. Cooper(The University of Texas MD Anderson Cancer Center), Christine E. Brown(City Of Hope National Medical Center), Stephen J. Forman(City Of Hope National Medical Center), Andrew Raubitschek
Cited by 367
Related Papers
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
|Blood|2017|1.1k
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
|Clinical Cancer Research|2015|754